Expert opinion on pharmacotherapy · 2008
Moxifloxacin: a respiratory fluoroquinolone.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miravitlles Marc, Anzueto Antonio
Аннотация
BACKGROUND: Respiratory quinolones are a class of antimicrobials with a high activity against most respiratory pathogens. Moxifloxacin is a fourth-generation fluoroquinolone that has been shown to be effective against Gram-positive, Gram-negative, and atypical strains, as well as multi-drug resistant Streptococcus pneumoniae.
OBJECTIVE: To review and update the clinical efficacy of moxifloxacin in the treatment of respiratory infections.
METHOD: To perform a systematic review of publications on the clinical efficacy of moxifloxacin in respiratory infections.
RESULTS: The clinical efficacy of moxifloxacin has been shown in controlled studies of community-acquired pneumonia, exacerbations of chronic bronchitis and acute bacterial rhinosinusitis. Moxifloxacin has demonstrated a faster resolution of symptoms in community-acquired pneumonia and exacerbations of chronic bronchitis patients compared with first-line therapy together with excellent eradication rates.
CONCLUSIONS: The use of moxifloxacin as first-line therapy for moderate to severe respiratory infections in the community and the hospital has been recognized in international guidelines.
OBJECTIVE: To review and update the clinical efficacy of moxifloxacin in the treatment of respiratory infections.
METHOD: To perform a systematic review of publications on the clinical efficacy of moxifloxacin in respiratory infections.
RESULTS: The clinical efficacy of moxifloxacin has been shown in controlled studies of community-acquired pneumonia, exacerbations of chronic bronchitis and acute bacterial rhinosinusitis. Moxifloxacin has demonstrated a faster resolution of symptoms in community-acquired pneumonia and exacerbations of chronic bronchitis patients compared with first-line therapy together with excellent eradication rates.
CONCLUSIONS: The use of moxifloxacin as first-line therapy for moderate to severe respiratory infections in the community and the hospital has been recognized in international guidelines.